
Symeres appoints Gabriella Gentile as chief operating officer
Charlie Blackie-Kelly | October 13, 2025 | Appointment | Research and Development | Symeres
Symeres, a mid-sized contract research, development and manufacturing organisation (CRDMO), has appointed Gabriella Gentile as its chief operating officer.
Operating across sites in the Netherlands, the Czech Republic, Finland and the US, Symeres provides integrated services for small molecules and other drug modalities, supporting clients from preclinical stages through to early clinical development and regulatory review.
In her new role, Gentile will oversee transformation initiatives across Symeres’ global operations, with a focus on expanding the company’s capabilities across the pharmaceutical value chain.
“[Gentile] brings a set of highly relevant skills and experience from both her background in medicinal chemistry, but also her decades of large pharma and biotech experience that will support the future growth plans of Symeres,” commented Guillaume Jetten, Symeres CEO.
Gentile has over 25 years of experience in the pharma, medical devices and services industries. Prior to joining Symeres, she served as global process improvement director at Catalent, where she was responsible for developing and implementing standardised operational frameworks across the company’s international network. Earlier in her career, she held leadership roles at Roche and Aptuit, working across operational and drug discovery functions.
“I’m delighted to join Symeres at this exciting time in their growth,” said Gabriella Gentile, “Symeres operates under a cultural philosophy of openness and transparency, and I look forward to being part of developing new next generation therapies.”
Related Content

Symeres announces acquisition of DGr Pharma
Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug …






